20/20 Biolabs, Inc. (AIDX) stock
AIDXNasdaqServices-Testing LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/3068% below fair value
$0.19+0.00 (+1.30%)
Close on Nov 17, 2026Market cap $2.39MP/E –Yield –
20/20 Biolabs operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
For fiscal 2025 it was -$3.33M.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$3.33M | – |
| FY2024 | Dec 31, 2024 | -$5.68M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$1.24M | – |
| Q1 FY2026 | Mar 31, 2026 | -$1.44M | – |
| Q2 FY2025 | Jun 30, 2025 | -$845.67K | – |
| Q1 FY2025 | Mar 31, 2025 | -$772.18K | – |
See a number that looks wrong?